Amy E. DeZern, MD, MHS
Oncology and Medicine
The Johns Hopkins University School of Medicine
Amy E. DeZern, MD, MHS, has disclosed that she has received consulting fees from Astex, Bristol-Myers Squibb, Gilead Sciences, and Novartis.
Daniel Pollyea, MD, MS
Professor of Medicine
Clinical Director of Leukemia Services
Associate Chief of Clinical Affairs
Robert H. Allen MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Daniel Pollyea, MD, MS, has disclosed that he has received funds for research support from AbbVie and consulting fees from AbbVie, Amgen, Celgene/Bristol-Myers Squibb, Genentech, Karyopharm, Kiadis, Novartis, Syndax, Syros, and Takeda.
Amer Zeidan, MBBS, MPH
Associate Professor, Internal Medicine
Leader, Leukemia and Myeloid Disease Aligned Research Team (DART)
Director, Hematology Early Therapeutics Research
Yale Cancer Center and Smilow Cancer Hospital
Yale University School of Medicine
New Haven, Connecticut
Amer Zeidan, MBBS, has disclosed that he has received funds for research support from AbbVie, ADC Therapeutics, Amgen, Aprea, Astex, Boehringer Ingelheim, Cardiff Oncology, Celgene/Bristol-Myers Squibb, Incyte, Medimmune/Astrazeneca, Novartis, Otsuka, Pfizer, Takeda, and Trovagene and consulting fees from Acceleron, Agios, Amgen, Aprea, Astellas, Astex, BeyondSpring, Boehringer Ingelheim, Cardiff Oncology, Cardinal Health, Celgene/Bristol-Myers Squibb, Daiichi Sankyo, Epizyme, Gilead Sciences, Incyte, Ionis, Janssen, Jazz, Kura, Novartis, Otsuka, Pfizer, Seattle Genetics, Syndax, Taiho, Takeda, Trovagene, and Tyme.